The effect of treatment with Selective Serotonin Reuptake Inhibitors incomparison to placebo in the progression of dementia: a systematic review and meta-analysis by Jones, Helen et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The effect of treatment with Selective Serotonin Reuptake
Inhibitors incomparison to placebo in the progression of
dementia: a systematic review and meta-analysis
Citation for published version:
Jones, H, Joshi, A, Shenkin, S & Mead, G 2016, 'The effect of treatment with Selective Serotonin Reuptake
Inhibitors incomparison to placebo in the progression of dementia: a systematic review and meta-analysis'
Age and Ageing. DOI: 10.1093/ageing/afw053
Digital Object Identifier (DOI):
10.1093/ageing/afw053
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Age and Ageing
Publisher Rights Statement:
This is the author's final peer-reviewed manuscript as accepted for publication
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
For Review Only
 
 
 
 
 
 
The effect of treatment with Selective Serotonin Reuptake 
Inhibitors in comparison to placebo in the progression of 
dementia: a systematic review and meta-analysis 
 
 
Journal: Age and Ageing 
Manuscript ID AA-15-0785.R1 
Manuscript Category: Systematic Review 
Keywords: SSRI, dementia, systematic review 
Keypoints: 
In patients with dementia there was no evidence of benefit or harm from 
SSRIs in terms of cognition, mood, agitation or ADLs., SSRIs were 
generally well tolerated with no increase in mortality but premature 
withdrawal from studies was high., Large, methodologically robust studies 
are required. 
  
 
 
For Review Only
 Revision Sheet 
 
 
Instructions for authors: 
 
1. In the first column please briefly summarise each point raised by the referee or editor. 
2. In the second column, briefly explain how you have responded to each point.  
3. In the third column, give the location in the text of the modification – with page and 
paragraph number reference. 
4. Please upload this form to Manuscript Central alongside your revised paper. 
 
  
Manuscript title: The effect of treatment with Selective Serotonin Reuptake Inhibitors in comparison to 
placebo in the progression of dementia: a systematic review and meta-analysis 
 
Please note that line number references linked to our responses correspond to the 
revised manuscript and not the manuscript with tracked changes.   
    
Referee 1  
 
Point raised by 
referee (please 
summarise)  
Response by author (briefly explain)  Location in 
text: 
Page and 
paragraph 
reference  
1. Is it possible to 
analyse the subtype 
of dementia such as 
Alzheimer Disease 
or other dementia? 
Thank you. We agree that this is an important issue. We have clarified in the 
abstract and paper that we include all subtypes of dementia (see response to 
reviewer 2). As stated in the methods (lines 142-146).  “Eight studies 
[15,16,20-22,24,26,28] restricted entry to only those with Alzheimer’s 
dementia and three [23,25,27] recruited participants with vascular dementia 
and/or Alzheimer's. One study only recruited participants with frontotemporal 
dementia using internationally agreed criteria for diagnosis [19].” 
 
We did not prespecify any subgroup analyses when the systematic review 
protocol was registered, so did not conduct these. Details on the dementia 
subtype are included in Table 1.  The studies included in the meta-analysis 
are all solely Alzheimer’s disease (AD) (except Petracca 2011 which was 
mixed AD and vascular dementia (VaD), and only provided 6.7% weighting).  
We have added the description of the dementia diagnosis to the results 
section (lines 180, 185, 207, 210, 216).  The studies where both AD and VaD 
were included did not provide data for dementia subtype separately, and only 
one study included fronto temporal dementia alone. We have added a 
sentence to the discussion (lines 335-340).  “The majority of studies (n=8) 
included only patients with Alzheimer’s disease (DSM III, DSM IV, or 
NINCDS-ADRDA criteria). Three included patients with either Alzheimer’s or 
vascular dementia, and one just patients with fronto-temporal dementia. Data 
were insufficient to establish if dementia subtype affected response to SSRI.” 
 
Lines 142-
146; page 11 
 
lines 
180,185; 
page 14 
 
lines 207, 
210; page 15 
 
line 216; 
page 16 
 
lines 335-
340; page 23 
2. Figure 2 is a low 
resolution image 
Many thanks for highlighting this.  The image has been reformatted.  All 
images have now also been uploaded as separate files in addition to 
embedding them into the text.   
Page 15 
3. With reference to 
the paper Sepehry 
et al 2012 
What is different 
from your study?  
Thank you for pointing out this interesting paper. Sepehry et al review 12 
studies (meta-analysis of six with 621 participants) of participants with 
Alzheimer’s disease and comorbid depression. This included four studies 
(Petracca et al, 2001, Banerjee et al, 2011, DIADS-1 and DIADS-2) that were 
included in our review, but two that were not (Magai, Rozzini). This study 
found no difference in post-treatment MMSE or depression scores in patients 
treated with SSRI or placebo. Our review specifically included subjects 
without concurrent depression, and with all dementia subtypes eligible for 
inclusion, and limited it to randomised control trials only.  We have included a 
section on this in the introduction (lines 60-65). 
Lines 60-
65;page 6 
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Referee 2 
 
Point raised by 
referee (please 
summarise)  
Response by author (briefly explain)  Location in 
text: 
Page and 
paragraph 
reference  
1. Important subject Thank you  
2. Why would one 
expect SSRIs to 
have any beneficial 
effect? 
 
This has been added into the introduction section (lines 49-55).  
 
Lines 49-55  
page 6  
3. All dementias or 
just Alzheimer 
disease?  
Thank you. We have clarified this in abstract and in methods section. See 
comments to reviewer 1. 
 
4. need to spell out 
"ALOIS" first time 
used 
“ALzheimer’s and cOgnitive Improvement Studies” register added to abstract 
and methods 
 
Line 10; page 
4, line 76; 
page 7 
5. Methods: what 
languages? 
English only.  This has been added into the methods section (line 77). Line 77; page 
7 
6. Methods: what 
kind of responses, 
from how many?  
 
Two authors kindly provided their continuous data on cognitive assessment.  
This information has been added (line 112-114). 
Lines 112-
114; page 9 
7. Isn't this finding 
re a lack of 
response in 
depression 
outcomes a bit 
surprising given that 
SSRIs are 
antidepressants? 
Makes the reader 
wonder about 
internal validity of 
the analysis? 
We agree, but it is consistent with an Health Technology Assessment funded 
randomised controlled trial of sertraline or mirtazapine in 326 patients 
(Banerjee et al, 2013, Health Technol Assess 2013;17:1–166) and the 
systematic review and meta-analysis of 621 patients Sepehry et al (2012) 
which shows no effect of SSRIs on patients with AD and concurrent 
depression, and suggests that they be used with caution and with an 
individualised approach. The lack of response could be a type II error, due to 
inadequate power in included studies, heterogeneity in included subjects, 
differences in outcome scales, short duration of follow-up, or may be a true 
negative: the effect of SSRIs on patients with dementia may be different than 
those without dementia. We have added a comment and this reference to the 
discussion (line 291). 
Line 291; 
page 21 
8. P19, line 8 
suggest change 
wording : "Kno 
increase in mortality 
with SSRI 
compared to 
placebo."  
 
Wording changed as per your recommendations above – “compared to 
placebo” has been added in (line 261).     
 
 
Line 261; 
page 20 
9. P 20 lines 14-
23.Why mention 
this? Isn't the 
purpose of a meta 
analysis to group 
and summarize 
data so we are not 
dependent on the 
results of only one 
study? 
We agree with your comment and as it does not add anything to the review it 
has been deleted.   
 
 
 
 
 
Associate Editor 
 
No action points required. 
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The effect of treatment with Selective 
Serotonin Reuptake Inhibitors in 
comparison to placebo in the 
progression of dementia:  
a systematic review and meta-analysis 
TRACKED CHANGES  
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Abstract 
 
Background: Selective serotonin reuptake inhibitors (SSRIs) may affect the 
neurodegenerative process of dementia, enhancing memory and cognition.  This 
systematic review aims to determine whether SSRIs influence cognitive 
performance, mood and function in people with any type of dementia.  
 
Method: Randomised placebo-controlled studies of SSRIs in people with dementia, 
which recorded cognitive outcomes, were identified in ALOIS (ALzheimer’s and 
cOgnitive Improvement Studies register) in April 2013 and updated in January 2015.  
Data were extracted on cognition, agitation, mood, activities of daily living (ADLs) 
and adverse events. End of treatment statistics were calculated.   
 
Results: Twelve studies met inclusion criteria (1174 participants), of which seven 
studies (710 participants) provided data for meta-analysis on cognition.  There was 
no difference in MMSE score at end of treatment; mean difference (MD) was 0.28 
(95%CI -0.83 to 1.39) (six studies,470 participants).  For change in MMSE scores, 
there was a small improvement; MD was 0.53 (95%CI -0.07 to 1.14) (three 
studies,352 participants).  The remaining studies showed no improvement in 
cognition.  There was no statistically significant benefit of SSRIs on mood (four 
studies,317 participants); standard mean difference (SMD) -0.10 (95%CI -0.39 to 
0.2), agitation (three studies,189 participants); SMD -0.01 (95%CI -0.86 to 0.83), or 
ADLs at end of treatment (four studies,336 participants); SMD -0.15 (95%CI -0.45 to 
0.15).  SSRIs were generally well tolerated with There was no difference no increase 
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in mortality between the two groups. Study quality was mixed with concerns over 
incomplete data.  
Conclusion:  A small number of relatively low-powered studies showed no benefit or 
harm from SSRIs in terms of Evidence from few studies shows neither benefit nor 
harm from SSRIs in terms of cognition, mood, agitation or ADLs.  Large, 
methodologically robust studies are needed. 
 
Key words:  SSRI, dementia, systematic review, placebo 
 
Key findings:  
In patients with dementia The available evidence from few studies shows 
neitherthere was no evidence of benefit or harm from SSRIs in terms of cognition, 
mood, agitation or ADLs.   
SSRIs were generally well tolerated with no increase in mortality but premature 
withdrawal from studies was high. 
Large, methodologically robust studies are required. 
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Background 
 
Selective Serotonin Reuptake Inhibitors (SSRIs) are effective in the treatment of 
depression [1], and other conditions such as obsessive–compulsive disorder, panic 
disorder, and bulimia [2], but whether they have a role in the treatment of dementia is 
unclear. SSRIs have been used to manage neuropsychiatric symptoms in dementia, 
for example, a recent Cochrane review by Seitz et al found some evidence to 
supported the use of certain antidepressants for agitation and psychosis[3], but they 
are not used clinically to stabilise or improve cognition.  
 
n theory, SSRIs could impact on the neurodegenerative process of dementia and 
help to enhance memory and cognition by promoting neurogenesis in the 
hippocampus [4].  Indeed, in patients with Alzheimer’s dementia, reduced levels of 
serotonin and precursors such as tryptophan have been demonstrated at post-
mortem [5]. SSRIs are highly selective for the neurotransmitter 5-hydroxytryptamine 
(5HT, serotonin) receptor and act by increasing the extracellular levels of serotonin 
through reuptake inhibition into the presynaptic cell [4].  In Alzheimer’s dementia, 
there are reduced levels of serotonin and its precursors such as tryptophan [5].  In 
theory, SSRIs could increase these, promote neurogenesis [6], encourage migration 
of new neurones to damaged brain areas [7] and decrease inflammation [8].  All of 
which in turn could affect neurodegeneration, and thus have an impact on cognition. 
 
A review of SSRIs in Alzheimer’s dementia suggested some indirect evidence to 
support SSRIs as cognitive enhancers, but Chow et al used both preclinical and 
human clinical trial evidence [6].  There was a suggestion of benefit from fluoxetine 
Comment [ 1]: This paragraph has been 
expanded below to include more on the 
biological plausibility of SSRIs 
Comment [ 2]: This paragraph has been 
rephrased and the review by Sepehry et al 
included   
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treatment in one trial of fluoxetine versus placebo in mild cognitive impairment; the 
only trial found in a systematic review on this topic, the sample size was small and 
further randomised clinical studies were recommended [7].  It is unclear whether 
SSRIs affect cognition in dementia.  A review including preclinical and clinical trials 
found some evidence to support SSRIs as cognitive enhancers [69].  A randomised 
control trial of fluoxetine versus placebo in mild cognitive impairment showed some 
improvement [10], whereas a meta-analysis of SSRIs in patients with Alzheimer’s 
disease and comorbid depression (six studies, 621paticipants) [11] found no effect 
on cognition or depression. 
 
There is therefore a need for an updated review of the evidence for use of SSRIs in 
patients not just with Alzheimer’s disease, but all subtypes of dementia, without 
limiting to those with a diagnosis of depression.  The primary purpose of this new 
review was to assess the effect of SSRI medications compared with placebo on 
cognitive performance in people with dementia.  Secondary outcomes were 
agitation, mood, the patient’s ability to perform activities of daily living (ADLs) and 
adverse events.  
 
Some studies have trialled SSRIs as a treatment for cognitive decline in dementia, 
and other studies investigating the effect of SSRIs on other outcomes such as mood 
have used cognition as an outcome measure, but there has been no recent 
systematic review of this evidence. 
 
 
Methods 
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Search Strategy 
The strategy was registered with Prospero in 2013: CRD42013003539 [812].  ALOIS 
(ALzheimer’s and cOgnitive Improvement Studies register) was used to identify all 
randomised controlled studies using SSRIs in dementia in English. ALOIS is a 
specialised open-access register maintained by Cochrane Dementia and Cognitive 
Improvement Group, derived from regular searches of a variety of major healthcare 
databases including MEDLINE and EMBASE [913].  The search was performed in 
April 2013 and then again in January 2015 to identify any new studies.   
 
The search was composed of the following terms: Selective Serotonin Reuptake 
Inhibitors; SSRI; citalopram; escitalopram; fluoxetine; fluvoxamine; paroxetine; and 
sertraline; combined with dementia (including subtypes).  (The full search strategy 
used is shown in Supplement 1 in Age and Ageing online). 
 
Selection Criteria 
Two authors (AJ and HJ) independently assessed all titles and abstracts, obtained 
full texts for potentially relevant studies and applied the following inclusion criteria: 
  
1. Study type: Published randomised placebo-controlled studies. Ongoing studies, 
studies not available in English and unpublished studies were excluded.  
2. Study group: Individuals with a diagnosis of any type of dementia according to 
standard criteria.  There was no age restriction and any type and severity of 
dementia was accepted.  Participants with an additional diagnosis of depression 
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were accepted.  Studies including participants with mild cognitive impairment 
and/or delirium without a distinct dementia group were excluded.  
3. Study intervention: Placebo-controlled studies of SSRIs.  Studies that referred 
to other antidepressants or used comparisons with other alternative active 
treatment were accepted if they included SSRI and placebo.   
4. Study outcomes: Cognitive performance assessed by a validated cognitive test. 
Only one cognitive test was chosen from each study based on our pre-
determined ranking system (Supplement 2 available in Age and Ageing 
online)[1014].  
Any discrepancy or uncertainty regarding the eligibility of a study was discussed with 
a third author (GM or SS) until consensus was reached.  If more than one publication 
reported data from the same participants, the publication which provided the most 
detail on our primary aim was used. Data was included as stated in the published 
papers, original protocols were not retrieved. Data from eligible studies were 
extracted by two independent reviewers (AJ and HJ) using a paper extraction form.  
Investigators were contacted for any missing data related to our primary aim. Two 
authors kindly responded and provided their continuous data on cognitive 
assessment [15,16].  
 
For studies with a placebo arm and two active arms, only data from the control arm 
and the SSRI arm were analysed. Methodological quality of included trials was 
assessed based on criteria listed in the Cochrane’s Reviewers Handbook [1117].  
Review Manager (RevMan5.1) software was used to calculate summary statistics at 
the end of intervention and follow-up using a random effects model [1218]. Where 
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studies used the same scale to measure an outcome, mMean difference (MD) was 
used if studies used the same scales for outcomes, . If different scales were used, 
standard mean difference (SMD) was presentedif not [1117]. Statistical heterogeneity 
between studies and subgroups was assessed by I2 statistic and interpreted 
according to the Cochrane Handbook. For dichotomous data, risk ratios (RRs) were 
reported.   
 
Results 
 
A total of 1928 study abstracts were assessed and 60 full texts were read (Figure 1).  
In total tTwelve studies met the inclusion criteria.   
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Figure 1. Flow diagram of selected studies  
 
 
Patient characteristics  
The 12 studies recruited a total of 1174 participants from nine countries  (Table 1). 
Seven studies recruited from outpatient clinics, three studies [24-26] recruited 
inpatients and two studies [15,27] did not report the source of participants. The 
number of participants in each trial (SSRI and placebo participants only) ranged from 
Comment [ 3]: all reference numbers have 
been altered due to the inclusion of new 
references earlier on  
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10 to 245, with five studies recruiting less than a total of 50 participants 
[15,19,22,23,25]. Nine studies [19-24,26-28] reported mean ages which 
rangedranging from 66.3 [19] to 80.9 years [24].  Eight studies [15,16,20-
22,24,26,28] restricted entry to only those with Alzheimer’s dementia and three 
[23,25,27] recruited participants with vascular dementia and/or Alzheimer's. One 
study only recruited participants with frontotemporal dementia using internationally 
agreed criteria for diagnosis [19]. Six [15,20,24-27] used DSM IV/DSM III (depending 
on the date of the study) as part of their inclusion criteriato diagnose dementia and 
five studies [16,21-23,28] used NINCDS-ADRD.  
One used internationally agreed criteria for frontotemporal dementia [13].    
 
Study Characteristics 
All 12 studies randomised participants to SSRI or placebo. Four used sertraline 
[15,20-22], three fluoxetine [15,23,26], three citalopram [24,27,28], one paroxetine 
[19] and one fluvoxamine [25]. Two studies had three arms: SSRI, placebo and a 
third treatment group [16,24]. The data from the third group have not been included 
in this review. In three studies [19,25,26], the primary aim was to assess efficacy of 
SSRI medications as a treatment for cognitive impairment in dementia. The 
remaining nine studies had this as a secondary aim.   
 
The duration of treatment ranged from 17 days [24] to 39 weeks [16],  with a mean of 
14.3 weeks.  In addition, sSome studies incorporated other phases into the study 
such as a wash out or open label phase.  In 11 studies, the dose of SSRI was 
gradually increased; some followed a set weekly regime, others allowed clinicians to 
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adjust doses based on response and tolerability [16,19-28].  Dose adjustment 
information was not available for one [15]. 
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Table 1: Studies included in systematic review of SSRIs and placebo in the progression of dementia (ordered by reference 
number) 
 
AUTHOR YEAR COUNTRY 
SAMPLE 
POPN 
ENTRY  
NUMBER  
DEMENTIA  
TYPE & CLASS 
AGE years* SEX (male)
‡
 SSRI USED 
ADDITIONAL 
GROUP 
[15] Auer  1996 USA - 
17 Fluoxetine                
13 Placebo               
Alzheimer’s Disease 
DSM IV 
- - Fluoxetine - 
[16] Banerjee 2011 UK Outpatient 
107 Sertraline            
111 Placebo                
Alzheimer’s Disease 
NINCDS-ADRDA  
- 
SSRI 32% 
Placebo 36% 
Sertraline Mirtazapine 
[19] Deakin 2003 UK Outpatient 
10 total  
(cross over trial) 
FTD  
internationally 
agreed criteria  
Total 
66.3(6.88)  
70%  Paroxetine - 
[20] Weintraub 2010 USA Outpatient 
67 Sertraline              
64 Placebo                      
Alzheimer’s Disease 
DSM IV 
SSRI  
76.5(8)  
Placebo 
78.2(8)  
 
54%  
Sertraline 
 
- 
[21] Finkel  2004 Finland Outpatient 
124 Sertraline 
121 Placebo 
Alzheimer’s Disease 
NINCDS-ADRDA 
Total 
76.3(7.5)  
SSRI 
75.7(7.7)  
Placebo 
76.9(7.4)  
43%  Sertraline - 
[22] Lyketsos 2003 USA Outpatient 
24 Sertraline 
20 Placebo 
Alzheimer’s Disease 
NINCDS-ADRDA  
Total  
77(8.4)  
SSRI 18% 
Placebo 50%  
Sertraline - 
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[23] Petracca 2001 Argentina Outpatient 
17 Fluoxetine 
24 Placebo 
Alzheimer’s Disease 
and vascular 
dementia         
NINCDS-ADRDA  
 
SSRI 
70.2(6.3)  
Placebo  
71.3 (6.9) 
SSRI 53%, 
Placebo 29% 
Fluoxetine - 
[24] Pollock  2002 USA Inpatient 
31 Citalopram               
21 Placebo                      
Alzheimer’s Disease  
DSM IV 
 
SSRI  
80.9(6.9)                              
Placebo 
78.5 (8.5) 
 
SSRI 79%              
Placebo 88% 
Citalopram Perphenazine 
[25] Olafsson 1992 Denmark Inpatient 
22 Fluvoxamine 
24 Placebo 
 
Alzheimer’s Disease 
Vascular Dementia 
DSM III  
SSRI 81
#
 
placebo 80
# 
SSRI 36% 
Placebo 46% 
Fluvoxamine - 
[26] Mowla  2007 Iran Inpatient 
41 Rivastigmine 
and Fluoxetine 
41 Rivastigmine 
and Placebo 
 
 
Alzheimer’s Disease 
DSM IV  
Total 69.2
† 
 46.5%  Fluoxetine - 
[27] Nyth  1990 
Sweden, 
Norway and 
Denmark 
- 
44 Citalopram  
45 Placebo 
 
Alzheimer’s Disease 
and vascular 
dementia            
DSM III  
Total 77.6
† 
 22% Citalopram - 
[28] Porsteinsson 2014 USA/Canada Outpatient 
94 Citalopram                  
92 Placebo                     
Alzheimer’s Disease 
NINCDS-ADRDA  
Total 78 (8) 
SSRI 78 (9) 
Placebo 
79 (8)   
 
15%  Citalopram - 
  *mean (standard deviation) unless stated otherwise. # median † No standard deviation given. ‡ Overall % unless otherwise stated. 
Abbreviations: FTD - Frontotemporal dementia. DSM III - Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition. DSM IV - Diagnostic and 
Statistical Manual of Mental Disorders, 4th Edition. NINCDS-ADRDA - National Institute of Neurological and Communicative Disorders and Stroke 
(NINCDS) and the Alzheimer’s Disease and Related Disorders Association (ADRDA) criteria. 
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All studies reported duration of treatment and measured outcomes at the end of 
treatment. For all but one trial [20], the end of treatment was the termination point of 
the trial with no subsequent follow-up reported.  
 
Cognition 
Mean score after treatment: There was no difference in mean MMSE (Mini Mental 
State Examination) scores at the end of treatment between SSRI and placebo 
groups. Duration of treatment for tTrials that used MMSE scoring was lasted 
between 6 [23] and 39 weeks [16] with a mean of 16.75 weeks.  Eight studies (841 
participants) [15,16,20-23,26,28] used MMSE to assess cognition before and end of 
treatment, with six (470 participants) [15,16,22,23,26,28] reporting the mean MMSE 
at end of treatment, allowing data to be combined in meta-analysis. The MD at the 
end of treatment was 0.28 MMSE points (95% CI -0.83 to 1.39) with moderate 
heterogeneity (I2 =38%, P=0.15) (Table 2, Figure 2a).  All of these studies except 
one small study [23] included solely patients with Alzheimer’s disease.  
However, one study within the meta-analysis [24] showed the SSRI group to have a 
statistically significantly better MMSE score at the end of treatment compared to 
placebo (MD=1.50, 95% CI 0.60 to 2.90) with no difference at baseline.  This study 
was considered to be of good quality and low-risk for all aspects of bias. 
 
Change in score after treatment: In studies that reported cognitive change, there was 
less cognitive decline when treated with SSRI.  Three of the eight studies (352 
participants) [15,21,26], all in patients with Alzheimer’s disease, reported the 
difference in MMSE scores between pre and postfollowing treatment; MD was 0.53 
(95% CI -0.07 to1.14), I2= 0% P=0.92,  Figure 2b). Unfortunately, iIt was not possible 
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to include all studies in the change of score analysis due to lack of availability of 
primary data.  
 
 
 
Figure 2a.  Mean MMSE scores at end of treatment (ordered by weighting) 
 
 
Figure 2b. Mean difference between MMSE scores before and after treatment 
(ordered weighting) 
 
  
 
One study [20] only presented median scores and so the data could not be 
incorporated into either meta-analysis, but found no difference between groups. The 
median score (1st, 3rd quartiles) at the end of treatment was 21 (16.5, 24) and 20 
(14.75, 24) in the control. Treatment effect was χ2= 0.5 (degrees of freedom 1); 
p=0.50. 
 
Four studies (196 participants) [19,24,25,27] including patients with Alzheimer’s, 
vascular or fronto-temporal dementia  using other cognitive tools also showed no 
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difference in cognition at the end of treatment with SSRI. One (10 participants) [19] 
found no significant differences on the Neuropsychiatric Inventory between 
paroxetine and placebo. For another one study in patients with Alzheimer’s disease 
[24], the Neurobehavioural Factor cognition score from baseline to study termination 
was approximately 0.22 for citalopram and 0.06 for placebo (readings taken from 
graph). Within the citalopram group this was a statistically significant improvement 
from baseline, however, the difference in the change of score between the 
citalopram and placebo group was not statistically significant.   Two studies Another 
study [21] in patients with Alzheimer's or vascular dementia found no difference in 
examined cognitive subscale scores on the GBS (Gottfries-Bråne-Steen) rating 
scale.   At the end of treatment the median (range) was 38 (10-62) in the SSRI group 
and 42 (12-60) with placebo in one study [25], and in the other . A further study [27] 
also showed no statistical difference between the groups on the GBS cognitive 
subscalethere was no difference between the groups (T=32 (51), p=0.321) (Table 2).  
The cognitive results of all the studies are detailed in Table 2. 
 
The quality of the studies, as reported, was mixed, and the results should be 
interpreted with caution.  affecting our confidence in the results.  For many studies, 
the proportion of incomplete outcome data was a concern and at risk of introducing 
bias. Across the 12 studies, 338 of 1174 participants (29%) withdrew prior to the final 
assessment.  At least 157 of these were from the SSRI group; one study [22] did not 
differentiate the groups from which the six participants withdrew. Six studies 
[16,21,23,25-27] had a significant drop out rate (defined as greater than> 5% [10]) 
and did not use intention-to-treat analysis.  There was no statistically significant 
difference between the two groups in terms of premature trial withdrawal; (T-value= 
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0.44 and p=0.66).  The main reasons for withdrawal were loss of efficacy, 
administrative reasons and adverse effects.  Several studies also lacked sufficient 
information to determine risk of bias in relation to randomisation, allocation and 
blinding methods.  The risk of bias for each trial is detailed in Supplement Table 1 
(available in Age and Ageing online).   
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AUTHOR 
Highest Ranking 
Cognition 
 Test 
1 
SSRI Cognition Score Placebo Cognition Score 
Other outcomes  
Baseline End of treatment Baseline End of treatment  
[15]     Auer  MMSE 12.94 (8.03) 11.77 (7.66) 13.30 (7.47) 11.85 (9.03) - 
[16]     Banerjee MMSE 18.5 (6.7) 17.4 (7.64) 18.2 (7.4)  18.63 (7.12) 
Mood, ADL impairment, 
Agitation, AE 
 
[19]     Deakin 
 
Neuropsychiatry  
Inventory  
- 32.4 (7.2)* - 28.8 (4.8)* - 
[20]     Weintraub MMSE 21(17,35)
#† 
21(16.5,24)
 #†
 19.5(15, 23.25)
 #†
 20 (14.75,24)
 #†
 
Mood, ADL impairment, 
Agitation, AE 
[21]     Finkel  MMSE 18.8 (0.5)* [0 (0.3)* 
‡
[ 18.0 (0.5)* [-0.6 (0.3)*
 ‡
] Mood, Agitation 
[22]     Lyketsos MMSE 17.5 (6.5) 16.1 (8.5) 16.3 (6.8) 16.8 (7.1) 
Mood, ADL impairment, 
Agitation, AE 
[23]     Petracca MMSE 23.2(4.5) 23.1 (6.8) 23.2 (5.3) 23.9 (5.9) 
Mood, ADL impairment, 
AE 
 
Table 2: Results of studies included in systematic review of SSRIs and placebo in the progression of dementia 
(ordered by reference number) 
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[24]     Pollock 
Neurobehavioral 
subscale 
- [0.22
‡
]  - [0.06
‡
] Mood, Agitation, AE 
 
[25]     Olafsson 
 
GBS subscale 43 (3-62)
#+ 
38 (10-62)
 #+
 40 (15-62)
 #+
 42(12-60)
 #+
 AE 
[26]     Mowla  MMSE 15.6 (0.73) 17.2 (0.63) 16.3 (4.1) 17.4 (3.7) 
Mood, ADL impairment, 
AE 
 
[27]     Nyth  GBS subscale 22.6 21.3 20.1 19.9 AE 
[28]     Porsteinsson MMSE 17.0 (6.2) 16.83 (2.95) 14.4 (6.9) 15.33 (2.93) 
Agitation, ADL 
impairment, AE, 
Data are mean cognition score (standard deviation) unless otherwise stated.  *SE(standard error) #median † (1
st
 and 3
rd
 quartiles) + (ranges) ‡ mean change in 
score from baseline (end treatment value not available). Abbreviations: MMSE: Mini Mental State Examination, GBS: Gottfries-Bthne-Steen geriatric rating scale, 
ADL: Activities of Daily Living, AE: Adverse Events. 
1 
Supplementary data 2  
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Mood 
There was no difference in depression outcomes in people with dementiamood at 
the end of treatment between the SSRI and placebo group.  Four studies (317 
participants) [16,22,23,26]  reported depression scores and demonstrated an SMD of  
-0.10 (95% CI, −0.39 to 0.2, I2=37% P=0.19; Supplementary Figure 1 available in 
Age and Ageing online).  The remaining eight studies either did not examine mood or 
did not report the results in a format compatible with the meta-analysis.  
 
Agitation 
There was no difference in mean agitation scores at the end of treatment. Three 
studies [19,24,28] reported agitation, of which two [19,28] could be included in our 
meta-analysis (189 participants); (SMD = -0.01, 95% CI -0.86 to 0.83, I2=70%, 
P=0.07); Supplementary Figure 2 available in Age and Ageing online).   The 
remaining trial [24] showed a significantly greater improvement in 
agitation/aggression (from baseline using the Neurobehavioural Factor Score) in the 
SSRI group (0.98) compared to placebo (0.38), (readings taken off graph; Kruskal-
Wallis test Χ2=6.7,df=2, p<0.04). Whilst this result is promising, methods used for 
concealment of allocation and randomisation were unclear, raising the possibility of 
selection bias.  Nine studies did not examine agitation as an outcome.  
 
Patient’s ability to perform activities of daily living  
There was no difference in a patient’s ability to complete ADLs between the two 
groups.  Four studies (336 participants) [22,23,26,28] reported participants’ ability to 
perform ADLs at the end of treatment; (SMD = -0.15, 95%CI -0.45 to 0.15, I2=41% 
P=0.17; Supplementary Figure 3 available in Age and Ageing online).  
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Adverse events and mortality 
There was no increase in mortality with SSRI compared to placebo. Four studies 
[16,20,27,28] (624 participants)  reported a combined total of 13 deaths. The risk 
ratio (RR) for death in the SSRI group was 0.91 (95% CI 0.33 to 2.50).  Adverse 
events were reported in all but two studies [15,19] and were collected either 
systematically or volunteered by the patient. The RR for the number of participants 
experiencing at least one adverse event was 1.25 (95%CI 0.67, to 2.31, I2=87% 
p<0.001) favouring placebo [16,20,27,28]. In studies reporting Other studies [15,18] 
reported tthe number of adverse events rather than the number of patients 
experiencing an event [21,23]. In these studies, there were 143 adverse events with 
sertraline,  compared to 1119 with placebo. One study  [24] found no significant 
change in total UK Side Effect Rating Scale score in any of the groups (F=1.49, df=2, 
81, p=0.23),. whilst 3 Three studies [22,25,26] just reported the most common side 
effects in both groups. Across the studies, these were typicallySide effects were 
gastrointestinal, neurological and autonomic disturbances.    
 
Discussion 
 
Summary of key findings 
Twelve completed studies comparing SSRIs with placebo were indentified, of which 
seven provided data that could be used in a meta-analysis on cognition [15,16,21-
23,26,28].  Sertraline was the most commonly used SSRI.  All participants had a 
formal diagnosis of dementia, mostly Alzheimer’s disease or vascular dementia, but 
none of the studies stipulated how long this had to have been present. Some, but not 
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all, studies required participants to have depression at the point of entry. The 
duration of treatment varied from days to months with a mean of 14.3 weeks. Only 
one study [19] followed up participants after treatment. 
Overall, there were no beneficial effects of SSRIs on cognition, with the meta-
analysis of MMSE scores at end of treatment demonstrating no statistically 
significant difference between SSRI and placebo.  However, one study [24] within 
the meta-analysis showed the SSRI group to have a significantly better MMSE score 
at the end of treatment compared to placebo.  The change in MMSE scores, 
although a much smaller analysis, showed a slight small improvement in favour of 
SSRIs.  However, this finding has to be interpreted with caution given the unclear 
quality of the included studies and concern over incomplete outcome data.  There 
was no statistical benefit of SSRI on mood, agitation or ADLs, though the number of 
studies is small and there was methodological bias in these studies.  SSRIs may not 
be effective in treating depression in patients with dementia [11,16]. The Number of 
deaths was low with no significant statistical difference between the groups. There 
was no statistically significant difference in side effects between the two groups., but 
a suggestion that there were more side-effects in those taking SSRIs. . 
 
 
Limitations of included studies 
It is possible that variations in the quality of the evidence may have influenced the 
results of this review.  The studies were generally small, the largest recruiting 245 
participants [21], and were of mixed quality, with many displaying multiple different 
sources of bias.  Some lacked important methodological detail, for example on 
sequence generation and allocation concealment, making it difficult to determine the 
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risk of bias.  The funding source was declared in the majority of the trials, with 
occasional links to the pharmaceutical industry (e.g. funding [21], provision of drugs 
[16]).   
 
All participants were generally recruited from tertiary centres, which often have more 
complex patients with more challenging symptoms. It is therefore unclear whether 
the findings can be extrapolated to the overall dementia population. The severity of 
dementia of participants included in the meta-analysis also varied, with mean scores 
ranging from 11 to 24 in the meta-analysis.  It is therefore also feasible that there 
may be differences in effect depending on the stage of disease.  Most studies did not 
exclude participants who also had concurrent depression and this could have acted 
as a confounding factor in influencing any changes to a patient’s cognition [29]. 
Cognition scores may have also been affected for other reasons, including hearing 
impairment or non-English speaking participants.  
 
The lack of long-term treatment and follow-up after treatment is a major limitation. 
From studies in participants with depression, it is known that SSRIs take time to 
show benefit and the dosage required can vary [2]. Some studies only lasted six 
weeks and had strict titration schedules. If cognitive tests are repeated there is the 
likelihood of practice effects, and this may mask a decline in cognition, though the 
effects would be similar in both groups. It is unlikely that cognitive change in a 
general, 30 point, cognitive test like the MMSE would be detectable over a period of 
several weeks.   Although there was no significance difference in the withdrawal rate 
between the SSRI and placebo groups, there was an overall high premature drop out 
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of 29% with lack of efficacy and side effects being the main reasons.  Ten studies 
reported side effects, but not all explained how these were collected. 
 
Limitations of the review 
The search criteria were deliberately broad to reduce the likelihood of any relevant 
published studies being missed when searching ALOIS. The main weakness of the 
search strategy was that any grey literature or unpublished studies would have been 
missed.  Reported data was not checked against original published protocols and so 
this review is reliant on the reporting of the primary investigators.   
The majority of studies (n=8) included only patients with Alzheimer’s disease (DSM 
III, DSM IV, or NINCDS-ADRDA criteria) [15,16,20-22,24,26,28] . Three included 
patients with either Alzheimer’s or vascular dementia [23,25,27], and one just 
patients with fronto-temporal dementia [19]. The majority of patients in the meta-
analysis had Alzheimer’s disease. Data were insufficient to establish if dementia 
subtype affected response to SSRI.  
 
Conclusion  
This review shows that aA small number of relatively low-powered studies show no 
benefit or harm from SSRIs in terms of cognitive outcomes in people with dementia, 
with one study suggestive of a small, statistically significant benefit. .There is 
insufficient data to say whether SSRIs are beneficial for cognition, and there is some 
suggestion of increased side effects. Future studies require adequate numbers of 
different dementia subtypes to allow subgroup analyses, a longer duration of follow-
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up, systematic reporting of adverse events, and clearer reporting of factors which 
may bias the results.  
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The effect of treatment with Selective 
Serotonin Reuptake Inhibitors in 
comparison to placebo in the 
progression of dementia:  
a systematic review and meta-analysis 
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Abstract 
 
Background: Selective serotonin reuptake inhibitors (SSRIs) may affect the 
neurodegenerative process of dementia, enhancing cognition.  This systematic 
review aims to determine whether SSRIs influence cognitive performance, mood and 
function in people with any type of dementia.  
 
Method: Randomised placebo-controlled studies of SSRIs in people with dementia, 
which recorded cognitive outcomes, were identified in ALOIS (ALzheimer’s and 
cOgnitive Improvement Studies register) in April 2013 and updated in January 2015.  
Data were extracted on cognition, agitation, mood, activities of daily living (ADLs) 
and adverse events. End of treatment statistics were calculated.   
 
Results: Twelve studies met inclusion criteria (1174 participants), of which seven 
studies (710 participants) provided data for meta-analysis on cognition.  There was 
no difference in MMSE score at end of treatment; mean difference (MD) was 
0.28(95%CI -0.83 to 1.39) (six studies,470 participants).  For change in MMSE 
scores, there was a small improvement; MD was 0.53(95%CI -0.07 to 1.14) (three 
studies,352 participants).  The remaining studies showed no improvement in 
cognition.  There was no statistically significant benefit of SSRIs on mood (four 
studies,317 participants); standard mean difference (SMD) -0.10(95%CI -0.39 to 
0.2), agitation (three studies,189 participants); SMD -0.01(95%CI -0.86 to 0.83), or 
ADLs at end of treatment (four studies,336 participants); SMD -0.15(95%CI -0.45 to 
0.15).  There was no difference in mortality between the two groups. Study quality 
was mixed with concerns over incomplete data.  
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Conclusion:  A small number of relatively low-powered studies showed no benefit or 
harm from SSRIs in terms of cognition, mood, agitation or ADLs.  Large, 
methodologically robust studies are needed. 
Key words:  SSRI, dementia, systematic review, placebo 
 
Key findings:  
In patients with dementia there was no evidence of benefit or harm from SSRIs in 
terms of cognition, mood, agitation or ADLs.   
SSRIs were generally well tolerated with no increase in mortality but premature 
withdrawal from studies was high. 
Large, methodologically robust studies are required. 
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Background 
 
Selective Serotonin Reuptake Inhibitors (SSRIs) are effective in the treatment of 
depression [1], and other conditions such as obsessive–compulsive disorder, panic 
disorder, and bulimia [2], but whether they have a role in the treatment of dementia is 
unclear. SSRIs have been used to manage neuropsychiatric symptoms in dementia, 
for example, a recent Cochrane review supported the use of certain antidepressants 
for agitation and psychosis[3], but they are not used clinically to stabilise or improve 
cognition.  
 
SSRIs are highly selective for the neurotransmitter 5-hydroxytryptamine (5HT, 
serotonin) receptor and act by increasing the extracellular levels of serotonin through 
reuptake inhibition into the presynaptic cell [4].  In Alzheimer’s dementia, there are 
reduced levels of serotonin and its precursors such as tryptophan [5].  In theory, 
SSRIs could increase these, promote neurogenesis [6], encourage migration of new 
neurones to damaged brain areas [7] and decrease inflammation [8].  All of which in 
turn could affect neurodegeneration and thus have an impact on cognition. 
 
It is unclear whether SSRIs affect cognition in dementia.  A review including 
preclinical and clinical trials found some evidence to support SSRIs as cognitive 
enhancers [9].  A randomised control trial of fluoxetine versus placebo in mild 
cognitive impairment showed some improvement [10], whereas a meta-analysis of 
SSRIs in patients with Alzheimer’s disease and comorbid depression (six studies, 
621paticipants) [11] found no effect on cognition or depression. 
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There is therefore a need for an updated review of the evidence for use of SSRIs in 
patients not just with Alzheimer’s disease, but all subtypes of dementia, without 
limiting to those with a diagnosis of depression.  The primary purpose of this new 
review was to assess the effect of SSRI medications compared with placebo on 
cognitive performance in people with dementia.  Secondary outcomes were 
agitation, mood, the patient’s ability to perform activities of daily living (ADLs) and 
adverse events.  
 
 
Methods 
 
Search Strategy 
The strategy was registered with Prospero in 2013: CRD42013003539 [12].  ALOIS 
(ALzheimer’s and cOgnitive Improvement Studies register) was used to identify all 
randomised controlled studies using SSRIs in dementia in English. ALOIS is a 
specialised open-access register maintained by Cochrane Dementia and Cognitive 
Improvement Group, derived from regular searches of a variety of major healthcare 
databases including MEDLINE and EMBASE [13].  The search was performed in 
April 2013 and then again in January 2015 to identify any new studies.   
 
The search was composed of the following terms: Selective Serotonin Reuptake 
Inhibitors; SSRI; citalopram; escitalopram; fluoxetine; fluvoxamine; paroxetine; and 
sertraline; combined with dementia (including subtypes).  (The full search strategy 
used is shown in Supplement 1 in Age and Ageing online). 
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Selection Criteria 
Two authors (AJ and HJ) independently assessed all titles and abstracts, obtained 
full texts for potentially relevant studies and applied the following inclusion criteria: 
  
1. Study type: Published randomised placebo-controlled studies. Ongoing studies, 
studies not available in English and unpublished studies were excluded.  
2. Study group: Individuals with a diagnosis of any type of dementia according to 
standard criteria.  There was no age restriction and any type and severity of 
dementia was accepted.  Participants with an additional diagnosis of depression 
were accepted.  Studies including participants with mild cognitive impairment 
and/or delirium without a distinct dementia group were excluded.  
3. Study intervention: Placebo-controlled studies of SSRIs.  Studies that referred 
to other antidepressants or used comparisons with other alternative active 
treatment were accepted if they included SSRI and placebo.   
4. Study outcomes: Cognitive performance assessed by a validated cognitive test. 
Only one cognitive test was chosen from each study based on our pre-
determined ranking system (Supplement 2 available in Age and Ageing 
online)[14].  
Any discrepancy or uncertainty regarding the eligibility of a study was discussed with 
a third author (GM or SS) until consensus was reached.  If more than one publication 
reported data from the same participants, the publication which provided the most 
detail on our primary aim was used. Data was included as stated in the published 
papers, original protocols were not retrieved. Data from eligible studies were 
extracted by two independent reviewers (AJ and HJ) using a paper extraction form.  
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Investigators were contacted for any missing data related to the primary aim. Two 
authors kindly responded and provided their continuous data on cognitive 
assessment [15,16]. 
 
For studies with a placebo arm and two active arms, only data from the control arm 
and the SSRI arm were analysed. Methodological quality of included trials was 
assessed based on criteria listed in the Cochrane’s Reviewers Handbook [17].  
Review Manager (RevMan5.1) software was used to calculate summary statistics at 
the end of intervention and follow-up using a random effects model [18]. Mean 
difference (MD) was used if studies used the same scales for outcomes,  standard 
mean difference (SMD) if not [17]. Statistical heterogeneity between studies and 
subgroups was assessed by I2 statistic and interpreted according to the Cochrane 
Handbook. For dichotomous data, risk ratios (RRs) were reported.   
 
 
Results 
 
1928 study abstracts were assessed and 60 full texts were read (Figure 1).  Twelve 
studies met the inclusion criteria.   
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Figure 1. Flow diagram of selected studies  
 
 
 
Patient characteristics  
The 12 studies recruited 1174 participants from nine countries (Table 1). Seven 
studies recruited from outpatient clinics, three studies [24-26] recruited inpatients 
and two studies [15,27] did not report the source of participants. The number of 
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participants in each trial (SSRI and placebo participants only) ranged from 10 to 245, 
with five studies recruiting less than 50 participants [15,19,22,23,25]. Nine studies 
[19-24,26-28] reported mean ages ranging from 66.3 [19] to 80.9 years [24].  Eight 
studies [15,16,20-22,24,26,28] restricted entry to only those with Alzheimer’s 
dementia and three [23,25,27] recruited participants with vascular dementia and/or 
Alzheimer's. One study only recruited participants with frontotemporal dementia 
using internationally agreed criteria for diagnosis [19]. Six [15,20,24-27] used DSM 
IV/DSM III (depending on the date of the study) to diagnose dementia and five 
[16,21-23,28] used NINCDS-ADRD.  
 
Study Characteristics 
All 12 studies randomised participants to SSRI or placebo. Four used sertraline 
[16,20-22], three fluoxetine [15,23,26], three citalopram [24,27,28], one paroxetine 
[19] and one fluvoxamine [25]. Two studies had three arms: SSRI, placebo and a 
third treatment group [16,24]. The data from the third group have not been included 
in this review. In three studies [19,25,26], the primary aim was to assess efficacy of 
SSRI medications as a treatment for cognitive impairment in dementia. The 
remaining nine studies had this as a secondary aim.   
 
The duration of treatment ranged from 17 days [24] to 39 weeks [16],  mean of 14.3 
weeks.  Some studies incorporated other phases into the study such as a wash out 
or open label phase.  In 11 studies, the dose of SSRI was gradually increased; some 
followed a set weekly regime, others allowed clinicians to adjust doses based on 
response and tolerability [16,19-28].  Dose adjustment information was not available 
for one study [15]. 
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Table 1: Studies included in systematic review of SSRIs and placebo in the progression of dementia (ordered by reference 
number) 
 
AUTHOR YEAR COUNTRY 
SAMPLE 
POPN 
ENTRY  
NUMBER  
DEMENTIA  
TYPE & CLASS 
AGE years* SEX (male)
‡
 SSRI USED 
ADDITIONAL 
GROUP 
[15] Auer  1996 USA - 
17 Fluoxetine                
13 Placebo                   
Alzheimer’s Disease 
DSM IV 
- - Fluoxetine - 
[16] Banerjee 2011 UK Outpatient 
107 Sertraline            
111 Placebo                
Alzheimer’s Disease 
NINCDS-ADRDA  
- 
SSRI 32% 
Placebo 36% 
Sertraline Mirtazapine 
[19] Deakin 2003 UK Outpatient 
10 total  
(cross over trial) 
FTD  
internationally 
agreed criteria  
Total 
66.3(6.88)  
70%  Paroxetine - 
[20] Weintraub 2010 USA Outpatient 
67 Sertraline              
64 Placebo                      
Alzheimer’s Disease 
DSM IV 
SSRI  
76.5(8)  
Placebo 
78.2(8)  
 
54%  
Sertraline 
 
- 
[21] Finkel  2004 Finland Outpatient 
124 Sertraline 
121 Placebo 
Alzheimer’s Disease 
NINCDS-ADRDA 
Total 
76.3(7.5)  
SSRI 
75.7(7.7)  
Placebo 
76.9(7.4)  
43%  Sertraline - 
[22] Lyketsos 2003 USA Outpatient 
24 Sertraline 
20 Placebo 
Alzheimer’s Disease 
NINCDS-ADRDA  
Total  
77(8.4)  
SSRI 18% 
Placebo 50%  
Sertraline - 
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[23] Petracca 2001 Argentina Outpatient 
17 Fluoxetine 
24 Placebo 
Alzheimer’s Disease 
and vascular 
dementia         
NINCDS-ADRDA  
 
SSRI 
70.2(6.3)  
Placebo  
71.3 (6.9) 
SSRI 53%, 
Placebo 29% 
Fluoxetine - 
[24] Pollock  2002 USA Inpatient 
31 Citalopram               
21 Placebo                      
Alzheimer’s Disease  
DSM IV 
 
SSRI  
80.9(6.9)                              
Placebo 
78.5 (8.5) 
 
SSRI 79%               
Placebo 88% 
Citalopram Perphenazine 
[25] Olafsson 1992 Denmark Inpatient 
22 Fluvoxamine 
24 Placebo 
 
Alzheimer’s Disease 
Vascular Dementia 
DSM III  
SSRI 81
#
 
placebo 80
# 
SSRI 36% 
Placebo 46% 
Fluvoxamine - 
[26] Mowla  2007 Iran Inpatient 
41 Rivastigmine 
and Fluoxetine 
41 Rivastigmine 
and Placebo 
 
 
Alzheimer’s Disease 
DSM IV  
Total 69.2
† 
 46.5%  Fluoxetine - 
[27] Nyth  1990 
Sweden, 
Norway and 
Denmark 
- 
44 Citalopram  
45 Placebo 
 
Alzheimer’s Disease 
and vascular 
dementia            
DSM III  
Total 77.6
† 
 22% Citalopram - 
[28] Porsteinsson 2014 USA/Canada Outpatient 
94 Citalopram                  
92 Placebo                     
Alzheimer’s Disease 
NINCDS-ADRDA  
Total 78 (8) 
SSRI 78 (9) 
Placebo 
79 (8)   
 
15%  Citalopram - 
  *mean (standard deviation) unless stated otherwise. # median † No standard deviation given. ‡ Overall % unless otherwise stated. 
Abbreviations: FTD - Frontotemporal dementia. DSM III - Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition. DSM IV - Diagnostic and 
Statistical Manual of Mental Disorders, 4th Edition. NINCDS-ADRDA - National Institute of Neurological and Communicative Disorders and Stroke 
(NINCDS) and the Alzheimer’s Disease and Related Disorders Association (ADRDA) criteria. 
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All studies reported duration of treatment and measured outcomes at the end of 
treatment. For all but one trial [20], the end of treatment was the termination point of 
the trial with no subsequent follow-up reported.  
 
Cognition 
Mean score after treatment: There was no difference in mean MMSE (Mini Mental 
State Examination) scores at the end of treatment between SSRI and placebo 
groups. Trials that used MMSE scoring lasted between 6 [23] and 39 weeks [16] 
mean of 16.75 weeks.  Eight studies (841 participants) [15,16,20-23,26,28] used 
MMSE to assess cognition before and end of treatment, with six (470 participants) 
[15,16,22,23,26,28] reporting the mean MMSE at end of treatment, allowing data to 
be combined in meta-analysis. The MD at the end of treatment was 0.28 MMSE 
points (95% CI -0.83 to 1.39) with moderate heterogeneity (I2 =38%, P=0.15) (Table 
2, Figure 2a).  All of these studies except one small study [23] included solely 
patients with Alzheimer’s disease.  
 
Change in score after treatment: In studies that reported cognitive change, there was 
less cognitive decline when treated with SSRI.  Three of the eight studies (352 
participants) [15,21,26], all in patients with Alzheimer’s disease, reported the 
difference in MMSE scores following treatment; MD was 0.53 (95% CI -0.07 to1.14), 
I2= 0% P=0.92,  Figure 2b). It was not possible to include all studies in the change of 
score analysis due to lack of availability of primary data.  
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Figure 2a.  Mean MMSE scores at end of treatment (ordered by weighting) 
 
 
Figure 2b. Mean difference between MMSE scores before and after treatment 
(ordered by weighting) 
 
  
 
One study [20] only presented median scores and so the data could not be 
incorporated into either meta-analysis, but found no difference between groups. The 
median score (1st, 3rd quartiles) at the end of treatment was 21 (16.5, 24) and 20 
(14.75, 24) in the control. Treatment effect was χ2= 0.5 (degrees of freedom 1); 
p=0.50. 
 
Four studies (196 participants) [19,24,25,27] including patients with Alzheimer’s, 
vascular or fronto-temporal dementia showed no difference in cognition at the end of 
treatment with SSRI. One (10 participants) [19] found no significant differences on 
the Neuropsychiatric Inventory between paroxetine and placebo. For one study in 
patients with Alzheimer’s disease [24], the Neurobehavioural Factor cognition score 
from baseline to study termination was approximately 0.22 for citalopram and 0.06 
for placebo (readings taken from graph). Within the citalopram group this was a 
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statistically significant improvement from baseline, however, the difference in the 
change of score between the citalopram and placebo group was not statistically 
significant. Two studies [25,27] in patients with Alzheimer's or vascular dementia 
found no difference in cognitive subscale scores on the GBS (Gottfries-Bråne-Steen) 
rating scale.   At the end of treatment the median (range) was 38 (10-62) in the SSRI 
group and 42 (12-60) with placebo in one study [25], and in the other [27] there was 
no difference between the groups (T=32 (51), p=0.321) (Table 2).   
The quality of the studies, as reported, was mixed, and the results should be 
interpreted with caution.   For many studies, the proportion of incomplete outcome 
data was a concern and at risk of introducing bias. Across the 12 studies, 338 of 
1174 participants (29%) withdrew prior to the final assessment.  At least 157 of these 
were from the SSRI group; one study [22] did not differentiate the groups from which 
the six participants withdrew. Six studies [16,21,23,25-27] had a significant drop out 
rate (>5% [10]) and did not use intention-to-treat analysis.  There was no statistically 
significant difference between the two groups in terms of premature trial withdrawal; 
(T-value= 0.44 and p=0.66).  The main reasons for withdrawal were loss of efficacy, 
administrative reasons and adverse effects.  Several studies also lacked sufficient 
information to determine risk of bias in relation to randomisation, allocation and 
blinding methods.  The risk of bias for each trial is detailed in Supplement Table 1 
(available in Age and Ageing online).   
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AUTHOR 
Highest Ranking 
Cognition 
 Test 
1 
SSRI Cognition Score Placebo Cognition Score 
Other outcomes  
Baseline End of treatment Baseline End of treatment  
[15]     Auer  MMSE 12.94 (8.03) 11.77 (7.66) 13.30 (7.47) 11.85 (9.03) - 
[16]     Banerjee MMSE 18.5 (6.7) 17.4 (7.64) 18.2 (7.4)  18.63 (7.12) 
Mood, ADL impairment, 
Agitation, AE 
 
[19]     Deakin 
 
Neuropsychiatry  
Inventory  
- 32.4 (7.2)* - 28.8 (4.8)* - 
[20]     Weintraub MMSE 21(17,35)
#† 
21(16.5,24)
 #†
 19.5(15, 23.25)
 #†
 20 (14.75,24)
 #†
 
Mood, ADL impairment, 
Agitation, AE 
[21]     Finkel  MMSE 18.8 (0.5)* [0 (0.3)* 
‡
[ 18.0 (0.5)* [-0.6 (0.3)*
 ‡
] Mood, Agitation 
[22]     Lyketsos MMSE 17.5 (6.5) 16.1 (8.5) 16.3 (6.8) 16.8 (7.1) 
Mood, ADL impairment, 
Agitation, AE 
[23]     Petracca MMSE 23.2(4.5) 23.1 (6.8) 23.2 (5.3) 23.9 (5.9) 
Mood, ADL impairment, 
AE 
 
Table 2: Results of studies included in systematic review of SSRIs and placebo in the progression of dementia 
(ordered by reference number) 
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[24]     Pollock 
Neurobehavioral 
subscale 
- [0.22
‡
]  - [0.06
‡
] Mood, Agitation, AE 
 
[25]     Olafsson 
 
GBS subscale 43 (3-62)
#+ 
38 (10-62)
 #+
 40 (15-62)
 #+
 42(12-60)
 #+
 AE 
[26]     Mowla  MMSE 15.6 (0.73) 17.2 (0.63) 16.3 (4.1) 17.4 (3.7) 
Mood, ADL impairment, 
AE 
 
[27]     Nyth  GBS subscale 22.6 21.3 20.1 19.9 AE 
[28]     Porsteinsson MMSE 17.0 (6.2) 16.83 (2.95) 14.4 (6.9) 15.33 (2.93) 
Agitation, ADL 
impairment, AE, 
Data are mean cognition score (standard deviation) unless otherwise stated.  *SE(standard error) #median † (1
st
 and 3
rd
 quartiles) + (ranges) ‡ mean change in 
score from baseline (end treatment value not available). Abbreviations: MMSE: Mini Mental State Examination, GBS: Gottfries-Bthne-Steen geriatric rating scale, 
ADL: Activities of Daily Living, AE: Adverse Events. 
1 
Supplementary data 2  
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Mood 
There was no difference in mood at the end of treatment between the SSRI and 
placebo group.  Four studies (317 participants) [16,22,23,26]  reported depression 
scores and demonstrated an SMD of  -0.10 (95% CI, −0.39 to 0.2, I2=37% P=0.19; 
Supplementary Figure 1 available in Age and Ageing online).  The remaining eight 
studies either did not examine mood or did not report the results in a format 
compatible with the meta-analysis.  
 
Agitation 
There was no difference in mean agitation scores at the end of treatment. Three 
studies [19,24,28] reported agitation, of which two [19,28] could be included in meta-
analysis (189 participants); (SMD = -0.01, 95% CI -0.86 to 0.83, I2=70%, P=0.07); 
Supplementary Figure 2 available in Age and Ageing online).   The remaining trial 
[24] showed a significantly greater improvement in agitation/aggression (from 
baseline using the Neurobehavioural Factor Score) in the SSRI group (0.98) 
compared to placebo (0.38), (readings taken off graph; Kruskal-Wallis test 
Χ2=6.7,df=2, p<0.04). Whilst this result is promising, methods used for concealment 
of allocation and randomisation were unclear, raising the possibility of selection bias.  
Nine studies did not examine agitation as an outcome.  
 
Patient’s ability to perform activities of daily living  
There was no difference in a patient’s ability to complete ADLs between the two 
groups.  Four studies (336 participants) [22,23,26,28] reported participants’ ability to 
perform ADLs at the end of treatment; (SMD = -0.15, 95%CI -0.45 to 0.15, I2=41% 
P=0.17; Supplementary Figure 3 available in Age and Ageing online).  
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Adverse events and mortality 
There was no increase in mortality with SSRI compared to placebo. Four studies 
[16,20,27,28] (624 participants) reported a total of 13 deaths. The risk ratio (RR) for 
death in the SSRI group was 0.91 (95% CI 0.33 to 2.50).  Adverse events were 
reported in all but two studies [15,19] and were collected either systematically or 
volunteered by the patient. RR for the number of participants experiencing at least 
one adverse event was 1.25 (95%CI 0.67, to 2.31, I2=87% p<0.001) favouring 
placebo [16,20,27,28]. In studies reporting the number of adverse events rather than 
the number of patients experiencing an event [21,23] there were 143 adverse events 
with sertraline, 119 with placebo. One study [24] found no significant change in total 
UK Side Effect Rating Scale score in any of the groups (F=1.49, df=2, 81, 
p=0.23).Three studies [22,25,26] reported the most common side effects in both 
groups. Side effects were gastrointestinal, neurological and autonomic disturbances.    
 
 
Discussion 
 
Summary of key findings 
Twelve completed studies comparing SSRIs with placebo were indentified, of which 
seven provided data that could be used in a meta-analysis on cognition [15,16,21-
23,26,28].  Sertraline was the most commonly used SSRI.  All participants had a 
formal diagnosis of dementia, mostly Alzheimer’s disease or vascular dementia, but 
none of the studies stipulated how long this had to have been present. Some, but not 
all, studies required participants to have depression at the point of entry. The 
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duration of treatment varied from days to months with a mean of 14.3 weeks. Only 
one study [19] followed up participants after treatment. 
 
Overall, there were no beneficial effects of SSRIs on cognition, with the meta-
analysis of MMSE scores at end of treatment demonstrating no statistically 
significant difference between SSRI and placebo.  There was no statistical benefit of 
SSRI on mood, agitation or ADLs, though the number of studies is small and there 
was methodological bias in these studies.  SSRIs may not be effective in treating 
depression in patients with dementia [11,16]. Number of deaths was low with no 
difference between the groups. There was no statistically significant difference in 
side effects between the two groups. 
 
Limitations of included studies 
It is possible that variations in the quality of the evidence may have influenced the 
results of this review.  The studies were generally small, the largest recruiting 245 
participants [21], and were of mixed quality, with many displaying multiple different 
sources of bias.  Some lacked important methodological detail, for example on 
sequence generation and allocation concealment, making it difficult to determine the 
risk of bias.  The funding source was declared in the majority of the trials, with 
occasional links to the pharmaceutical industry (e.g. funding [21], provision of drugs 
[16]).   
 
All participants were generally recruited from tertiary centres, which often have more 
complex patients with more challenging symptoms. It is therefore unclear whether 
the findings can be extrapolated to the overall dementia population. The severity of 
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dementia of participants included in the meta-analysis also varied, with mean scores 
ranging from 11 to 24 in the meta-analysis.  It is therefore also feasible that there 
may be differences in effect depending on the stage of disease.  Most studies did not 
exclude participants who also had concurrent depression and this could have acted 
as a confounding factor in influencing any changes to a patient’s cognition [29]. 
Cognition scores may have also been affected for other reasons, including hearing 
impairment or non-English speaking participants.  
 
The lack of long-term treatment and follow-up after treatment is a major limitation. 
From studies in participants with depression, it is known that SSRIs take time to 
show benefit and the dosage required can vary [2]. Some studies only lasted six 
weeks and had strict titration schedules. If cognitive tests are repeated there is the 
likelihood of practice effects, and this may mask a decline in cognition, though the 
effects would be similar in both groups. It is unlikely that cognitive change in a 
general, 30 point, cognitive test like the MMSE would be detectable over a period of 
several weeks.   Although there was no significance difference in the withdrawal rate 
between the SSRI and placebo groups, there was an overall high premature drop out 
of 29% with lack of efficacy and side effects being the main reasons.  Ten studies 
reported side effects, but not all explained how these were collected. 
 
Limitations of the review 
The search criteria were deliberately broad to reduce the likelihood of any relevant 
published studies being missed when searching ALOIS. The main weakness of the 
search strategy was that any grey literature or unpublished studies would have been 
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missed.  Reported data was not checked against original published protocols and so 
this review is reliant on the reporting of the primary investigators.   
The majority of studies (n=8) included only patients with Alzheimer’s disease (DSM 
III, DSM IV, or NINCDS-ADRDA criteria) [15,16,20-22,24,26,28] . Three included 
patients with either Alzheimer’s or vascular dementia [23,25,27], and one just 
patients with fronto-temporal dementia [19]. The majority of patients in the meta-
analysis had Alzheimer’s disease. Data were insufficient to establish if dementia 
subtype affected response to SSRI.  
 
 
Conclusion  
A small number of relatively low-powered studies show no benefit or harm from 
SSRIs in terms of cognitive outcomes in people with dementia.  There is insufficient 
data to say whether SSRIs are beneficial for cognition, and there is some suggestion 
of increased side effects. Future studies require adequate numbers of different 
dementia subtypes to allow subgroup analyses, a longer duration of follow-up, 
systematic reporting of adverse events, and clearer reporting of factors which may 
bias the results.  
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PRISMA 2009 Checklist 
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.   
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.   
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).   
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis.  
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PRISMA 2009 Checklist 
Section/topic  # Checklist item  Reported on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).   
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.   
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).   
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).   
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.   
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. 
doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
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Supplements  
 
Supplement 1: Search strategy used in ALOIS April 2013 and again January 2015 
 
1. Dementia OR Alzheimer Disease OR AD OR Alzheimer OR Alzheimers OR 
Alzheimer’s OR Lewy Body Disease OR Lewy Body OR Lewy OR Vascular 
dementia 
AND 
2. SSRI OR SSRIs OR Selective Serotonin Reuptake Inhibitors OR Citalopram 
Escitalopram OR Fluoxetine OR  Sertraline OR Fluvoxamine OR  Paroxetine 
 
 
Supplement 2: Predetermined ranking system for inclusion of cognitive tests1   
1. Mini Mental State Examination  (MMSE) 
2. Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS –Cog) 
3. Addenbrooke’s Cognitive Examination (Revised) (ACE-R) 
4. The General Practitioner assessment of Cognition (GPCOG) 
5. Montreal Cognitive Assessment  (MoCA) – clinical diagnosis only 
6. The 6 Item Cognitive Impairment Test (6-CIT) – clinical diagnosis only 
7. Neurobehavioural Rating Scale - cognition component 
8. Gottfries-Bthne-Steen geriatric rating scale - cognition component  
9. Neuropsychiatric Inventory – cognition component 
 
 
 
 
 
 
 
1
Sheehan B. Assessment scales in dementia. Therapeutic Advances in Neurological Disorders. 2012;5(6):349-358.  
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Supplementary Table 1: Risk of Bias (alphabetical order) 
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Supplement Figure 1. Mean mood scores at the end of treatment (ordered by 
weighting)  
Study or Subgroup
Petracca 2001
Lyketsos 2003
Mowla 2007
Banerjee 2011
Total (95% CI)
Heterogeneity: Tau² = 0.03; Chi² = 4.73, df = 3 (P = 0.19); I² = 37%
Test for overall effect: Z = 0.64 (P = 0.52)
Mean
9.4
10.3
6.55
8.5
SD
5.7
7.7
0.32
8.5
Total
17
24
41
68
150
Mean
10
14.9
6.26
8.5
SD
5.1
5.5
2.9
5.5
Total
24
20
41
82
167
Weight
17.0%
17.5%
27.7%
37.8%
100.0%
IV, Random, 95% CI
-0.11 [-0.73, 0.51]
-0.66 [-1.28, -0.05]
0.14 [-0.29, 0.57]
0.00 [-0.32, 0.32]
-0.10 [-0.39, 0.20]
Favours SSRI Favours placebo Std. Mean Difference Std. Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favours SSRI Favours placebo
 
 
Supplement Figure 2: Mean agitation scores at end of treatment (ordered by 
weighting)  
Study or Subgroup
Deakin
Porsteinsson 2014
Total (95% CI)
Heterogeneity: Tau² = 0.28; Chi² = 3.38, df = 1 (P = 0.07); I² = 70%
Test for overall effect: Z = 0.03 (P = 0.97)
Mean
-32.4
-4.33
SD
7.2
2.87
Total
10
86
96
Mean
-28.8
-5.26
SD
4.8
2.82
Total
10
83
93
Weight
38.2%
61.8%
100.0%
IV, Random, 95% CI
-0.56 [-1.46, 0.33]
0.33 [0.02, 0.63]
-0.01 [-0.86, 0.83]
Favour SSRI Favour Placebo Std. Mean Difference Std. Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favours SSRI Favours Placebo
 
 
Supplement Figure 3: Mean activities of daily living (ADL) scores at end of 
treatment (ordered by weighting)  
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Figure 1. Flow diagram of selected studies  
254x293mm (72 x 72 DPI)  
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Figure 2a.  Mean MMSE scores at end of treatment (ordered by weighting)  
270x73mm (72 x 72 DPI)  
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Figure 2b. Mean difference between MMSE scores before and after treatment (ordered by weighting)  
 
255x56mm (72 x 72 DPI)  
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Supplementary Table 1: Risk of Bias (alphabetical order)  
 
+ low risk of bias, ? unclear risk of bias, - high risk of bias  
109x247mm (72 x 72 DPI)  
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Supplement Figure 1. Mean mood scores at the end of treatment (ordered by weighting)    
291x62mm (72 x 72 DPI)  
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Supplement Figure 2: Mean agitation scores at end of treatment (ordered by weighting)  
289x50mm (72 x 72 DPI)  
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Supplement Figure 3: Mean activities of daily living (ADL) scores at end of treatment (ordered by weighting) 
299x62mm (72 x 72 DPI)  
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